We’ve got your-need-to-know tricks for keeping the peace at home
Cellcom Israel Ltd., ("Cellcom Israel" or "the Company") (NYSE: CEL)(TASE: CEL) today announced that it intends to consolidate the listing of its shares onto one single exchange, the Tel Aviv Stock Exchange ("TASE"). The Company will maintain the current listing of its shares on TASE, which will become Cellcom Israel's primary and only listing.
The CNN anchor laid bare the senator's hypocrisy after he said Biden would be weak if he didn't oppose Trump's impeachment.
PARIS and CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, today announces that it plans to publicly file a registration statement on Form F-1 with the U.S. Securities and Exchange Commission (the “SEC”) today in relation to a proposed initial public offering of ordinary shares in the form of American Depositary Shares (the “ADSs”) in the United States (the “ADS Offering”) and proposed Nasdaq listing in connection therewith. All securities to be sold in the ADS Offering will be offered by Biophytis. The number of securities, including the ratio of ordinary shares to ADS, and the price range of the securities to be sold in the ADS Offering have not yet been determined. About Biophytis Biophytis SA is a clinical-stage biotechnology company specialized in the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19. The company is based in Paris, France, and Cambridge, Massachusetts. The company's common shares are listed on the Euronext Growth Paris market (Ticker: ALBPS -ISIN: FR0012816825). DisclaimerThis press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. In some cases, you can identify these forward-looking statements by the use of words such as "outlook," "believes," "expects," "potential," "continues," "may," "will," "should," "could," "seeks," "predicts," "intends," "trends," "plans," "estimates," "anticipates" or the negative version of these words or other comparable words. These forward-looking statements include certain statements regarding Biophytis’ proposed initial public offering as well as its business, including its prospects and product development. Such forward-looking statements are based on assumptions that Biophytis considers to be reasonable. However, there can be no assurance that the statements contained in such forward-looking statements will be verified, which are subject to various risks and uncertainties including, without limitation, risks inherent in the development and/or commercialization of potential products, the outcome of its studies, uncertainty in the results of pre-clinical and clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. The forward-looking statements contained in this press release are also subject to risks not yet known to Biophytis or not currently considered material by Biophytis. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. These factors include but are not limited to those described under "Risk Factors" in Biophytis’ registration statement relating to the initial public offering. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in the registration statement. We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law. No communication or information relating to the ADS Offering by Biophytis may be transmitted to the public in a country where there is a registration obligation or where an approval is required. The issuance or the subscription of the securities of the Company may be subject to legal and regulatory restrictions in certain jurisdictions; none of Biophytis and the bank involved in the ADS Offering assumes any liability in connection with the breach by any person of such restrictions. This press release is an advertisement and not a prospectus within the meaning of Directive 2003/71/EC of the European Parliament and the Council of 4 November 2003, as amended or superseded including by Directive 2010/73/EU and as implemented in each member state of the European Economic Area, and of EU Regulation 2017/1129 as supplemented by EU Regulation 2019/980 (the “Prospectus Regulations”). This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to any securities of Biophytis in any country. This press release is not an offer to the public, an offer to subscribe or designed to solicit interest for purposes of an offer to the public in any jurisdiction, including France. This press release was written in French and English. If there is a difference between the texts, the French version will prevail. Biophytis Investor Relations Contact Media ContactEvelyne Nguyen – CFO LifeSci AdvisorsEvelyne.nguyen@biophytis.com Sophie Beaumont sophie@lifesciadvisors.com Mobile: +33 (0)6 27 74 74 49 Investor Relations LifeSci Advisors, LLC Sandya von der Weid E: svonderweid@lifesciadvisors.com T: +41 78 680 05 38 PDF: http://ml.globenewswire.com/Resource/Download/23ed1925-d4e3-4e19-9b34-d87c7e9934ab
How can we get a refund from Virgin Atlantic?. We are owed £1,163 for cancelled flights and have been waiting for many months
For four years the outrages piled up so high they were hard to keep track of but the coronavirus pandemic proved to be one crisis he couldn’t bluster away Donald Trump holds a campaign rally at Pittsburgh-Butler regional airport in Butler, Pennsylvania , on 31 October. Photograph: Carlos Barría/Reuters Sign up for the Guardian’s First Thing newsletter In a cold, sombre, damp Washington four years ago this Wednesday, Donald Trump took the oath of office as the 45th president of the United States and delivered an inaugural address now remembered for two words: American carnage. He delivered, but not as he promised. Trump pledged to end the carnage of inner-city poverty, rusting factories, broken schools and the scourge of criminal gangs and drugs. Instead his presidency visited upon the nation the carnage of about 400,000 coronavirus deaths, the worst year for jobs since the second world war and the biggest stress test for American democracy since the civil war. “It’s not just physical carnage,” said Moe Vela, a former White House official. “There’s also mental carnage and there’s spiritual carnage and there’s emotional carnage. He has left a very wide swath of American carnage and that is the last way I would want to be remembered by history, but that is how he will be remembered.” Trump campaigned for president as a change agent but millions came to regard him as an agent of chaos. His line-crossing, envelope-pushing, wrecking-ball reign at the White House crashed in a fireball of lies about his election defeat and deadly insurrection at the US Capitol. Future generations of schoolchildren will read about him in textbooks as a twice-impeached one-term president. It all began in earnest in June 2015 when the property tycoon trundled down an escalator at Trump Tower in New York and announced a presidential run based on “America first” nationalism and building a border wall. Exploiting white grievance, economic dislocation and celebrity culture, he clinched the Republican nomination and promised: “I alone can fix it.” He lost the national popular vote to Hillary Clinton but lucked his way to victory in the electoral college. The first person elected to the White House with no previous political or military experience, he represented a shock to the system and rebuke to the establishment. Ian McEwan, the British novelist, observed in the Guardian: “Charles Darwin could not believe that a kindly God would create a parasitic wasp that injects its eggs into the body of a caterpillar so that the larva may consume the host alive … We may share his bewilderment as we contemplate the American body politic and what vile thing now squats within it, waiting to be hatched and begin its meal.” Trump tosses out ‘Keep America Great’ caps at a campaign rally at Oakland County international airport in Waterford Township, Michigan, in October 2020. Photograph: Carlos Barría/Reuters Hopes that Trump would “pivot” and become “presidential” were dashed by that speech on 20 January 2017. A day later, the press secretary, Sean Spicer, tried to mislead the nation about the size of the inaugural crowd, and soon after the White House counsellor Kellyanne Conway was defending Spicer’s “alternative facts”. It was the outbreak of a disinformation pandemic. Trump, by all accounts, tried to govern by gut instinct, refusing to read national security briefs but hanging on the words of hosts on the Fox News network. His Twitter feed gave an astonishing window on his thinking and frayed the nation’s nerves. He showed a narcissist’s craving for attention from the media and affirmation from West Wing staff, who came and went at a record rate. He assailed government bureaucracy, sought to undo Barack Obama’s legacy and displayed the brashness and shamelessness that served his business career: hurl insults, never apologize, hit back harder and throw out constant distractions. He aped demagogues of the past by handing his family top jobs and deriding the media as “fake news” and “the enemy of the people”. In his first year alone, Trump signed an executive order to prevent people from seven Muslim-majority countries from entering the US, fired the FBI director, James Comey, and other officials whose loyalty was less than absolute, announced America’s withdrawal from the Paris climate agreement and responded to deadly white nationalist violence in Charlottesville, Virginia, by insisting that there were “very fine people on both sides”. Donald Trump is the first president in my lifetime who does not try to unite the American people Jim Mattis As his term went on, Trump oversaw a “zero-tolerance” policy at the border that separated immigrant parents from children and stripped away environmental regulations. He encouraged the QAnon conspiracy movement, described as a domestic terror threat by the FBI. In language often laced with violent imagery, it was all about “owning the libs” and mesmerising the “Make America great again” base at cultish rallies. Jim Mattis, a retired four-star Marine Corps general who served as his first defence secretary, said last year: “Donald Trump is the first president in my lifetime who does not try to unite the American people – does not even pretend to try. Instead he tries to divide us.” Yet for three years, his beginner’s luck held and re-election seemed possible. An investigation into links between Russian meddling in the 2016 election and Trump’s campaign led to several criminal convictions but ultimately ended in anticlimax. He was impeached by the House of Representatives for pressuring Ukraine for political favours but was comfortably acquitted by the Senate. Trump gratified Republicans by naming three supreme court justices and more than 220 federal judges, giving the judiciary an enduring conservative bent, and enacting the biggest tax cuts and reforms for a generation. He invested in the military and brought troops home, negotiated a new trade deal with Canada and Mexico and helped broker agreements between close ally Israel and three Arab states. Trump observes a demonstration with the US army’s 10th Mountain Division troops, an attack helicopter and artillery, as he visits Fort Drum, New York, in August 2018. Photograph: Carlos Barría/Reuters Newt Gingrich, a former Republican House speaker, said: “It was a remarkably effective populist disruption of the old order. It changed regulations, it rebuilt the American military, it recentred American foreign policy on American interests, it renegotiated trade policy around American jobs, it began to fundamentally shift the judiciary system back to a constitutional basis. And at the same time it was generating economic growth so you had the lowest Black and Latino unemployment in American history.” Using a term that had led to widespread criticism of Trump for fuelling racism, Gingrich added: “Except for the enormous intrusion of the Chinese virus, it was an astonishingly successful period.” But the coronavirus did change everything. From the start, Trump deliberately played down the threat and failed to build a national testing strategy. He sidelined public health officials by refusing to embrace mask-wearing and suggesting unproven treatments, including the injection of disinfectant, and was eventually hospitalised with the virus himself. Vaccines came at historic speed but their distribution lagged and was described by President-elect Joe Biden as a “dismal failure”. Trump was a symptom of many problems, not the cause Arisha Hatch The summer brought another crisis. Faced with mass protests against racial injustice, Trump responded with brute force, law-and-order rhetoric and a renewed culture war over statues and Confederate symbols. On 1 June, security forces chased away peaceful protesters with teargas outside the White House before the president staged a photo op, awkwardly clutching a Bible at a historic church. But for every action, there is an equal and opposite reaction. The Trump era was also the era of #MeToo and Black Lives Matter. His inauguration was immediately followed by women’s marches including a record 4 million people in Washington. The “resistance” was maintained by activists, journalists, politicians, satirists, watchdogs, whistleblowers and voters, who delivered their verdict by handing Democrats the House, then the White House, then the Senate. By tapping America’s id, the president inadvertently did it a favor by bringing all its internal tensions and tormented histories to the surface, making them far harder to deny. Arisha Hatch, vice-president of the activist group Color of Change, said: “Trump’s four years in office led to a huge degree of suffering but it will also be remembered as a time of racial reckoning, a time when racial justice finally became a majoritarian issue. “Trump will be remembered for exposing the flaws in our democracy that have, for decades, kept us from achieving racial equity. Trump was a symptom of many problems, not the cause.” Trump hosts a coronavirus response task force briefing at the White House in July 2020. Photograph: Kevin Lamarque/Reuters Trump once boasted that he could shoot somebody on New York’s Fifth Avenue and not lose any voters, an insight vindicated time and again, including when he grew his support from 63m votes in 2016 to 74m in 2020, more than any incumbent president in history. But his opponent, Biden, gained a record 81m votes and won 306-232 in the electoral college. Trump refused to concede and launched a scorched earth campaign of lawsuits, fantasies and propaganda to overturn the result. But the officials, courts, civil society and media held firm. As Trump turned on his closest allies, including even Vice-President Mike Pence, weeks of election denialism and years of inflammatory rhetoric reached a fiery climax when a mob sacked the US Capitol, flaunting the Confederate flag and other far-right iconography. Five people died and members of Congress cowered in fear. That was the first time I thought, ‘It really could happen here’ Gwenda Blair Gwenda Blair, a Trump biographer, said: “That was perhaps the first time I was truly shocked and truly, personally, physically frightened. I’ve been frightened on every other level before but that was the first time I thought, ‘It really could happen here’. It was the first time that all of the norms and all the notions of it being somewhere else were completely blown away.” Blair was interviewed by the Guardian in a New York diner in July 2015 as Trump began his political ascent. Looking back on all that has happened since then, she reflected: “It’s a combination of exactly what I expected and worse than I could have imagined. It’s utterly consistent with his entire career but, even as someone who has been watching him for more than 30 years, it’s hard to wrap my mind around.” From carnival barker to world’s most powerful man, Trump, 74, leaves a legacy of division, destruction and death. He accelerated Americans’ distrust in institutions and in each other, waging war on truth itself. He still has millions of acolytes whose divorce from the reality of a Biden’s presidency threatens further instability and violence from domestic terrorists. Overseas, Trump made America an object of ridicule, scorn or pity as he gravitated towards foreign autocrats and alienated longtime allies. Trump speaks at the Suresnes American Cemetery and Memorial in Paris, France, on 11 November 2018. Photograph: Carlos Barría/Reuters Leon Panetta, a former defence secretary and CIA director, said: “Future historians will say that it was perhaps the worst presidency the United States has had because of the person Trump is and because he had little respect for the values associated with the presidency, did not believe that there were any rules that constrained him and generally undermined the strength of the United States at a very critical time, both at home and abroad.” But on Wednesday the lights will go out on the reality TV presidency as Trump exits the White House in defeat and disgrace, facing another impeachment trial in the Senate. A Pew Research Center poll found that his approval rating has collapsed to 29%, the lowest of his presidency. He has even been banned from social media, depriving him of the Twitter megaphone that gave diplomats and journalists sleepless nights. In addition to being the worst president, he’s a terrible person. What a combination Larry Sabato Biden will be inaugurated in a city resembling a fortress and begin clearing up four years of carnage. Former president Gerald Ford’s proclamation after the departure of Richard Nixon – “our long national nightmare is over” – will be widely quoted. Many will hope that Trump was a mere heartbeat in historical terms, a blip as the baton passed from Obama to Biden, and a warning to the future: let’s not do that again. Larry Sabato, director of the Center for Politics at the University of Virginia, said: “If history is honest, it will remember Donald Trump as by far the worst president ever. No one else even comes close. Not Warren Harding, not James Buchanan, not Richard Nixon. Nobody comes close. “And beyond that he is, in my view, the most horrible human being who has ever sat in the Oval Office. In addition to being the worst president, he’s a terrible person. What a combination. I hope we’ve learned this lesson. This ought to remind all Americans what happens when you make a mistake with your vote.”
Voyager Digital Ltd. ("Voyager" or the "Company") (CSE: VYGR) (OTCQB: VYGVF) (FRA: UCD2), a publicly-traded, licensed crypto-asset broker that provides investors with a turnkey solution to trade crypto assets, today announced the listing of the Terra (LUNA) Token on the Voyager platform, expanding Voyager's industry-leading offering to 57 digital assets.
Despite the tremendous challenges brought about by the COVID-19 pandemic and the rapid changes it's made to the workplace, both Warba Bank and Eurisko Mobility have continued their uninterrupted work on transforming the Bank's digital services.
Top companies covered are ACL AIRSHOP (The U.S.), Brambles Group (Australia), Cargo Composites (The U.S.), CSafe Global (The U.S.), Dokasch GmbH (Germany), Envirotainer AB (Sweden), Nordisk Aviation Products AS (Norway), Palnet GmbH Air Cargo Products (Germany), Satco, Inc. (The U.S.), TransDigm Group Incorporated (The U.S.), VRR Aviation (The Netherland), Zodiac Aerospace (France) and more players profiled in unit load device market research reportPune, India, Jan. 19, 2021 (GLOBE NEWSWIRE) -- The global unit load device market is expected to gain momentum by reaching USD 2.67 billion by 2027 while exhibiting a CAGR of 4.38% between 2020 and 2027. This is attributable to the rising aviation sector and the growing adoption of advanced technologies such as the internet of things (IoT) that is likely to drive the demand for innovative unit load devices across the globe. Fortune Business Insights, in its latest report, titled, “Unit Load Device Market Size, Share & COVID-19 Impact Analysis, By Product Type (LD 3 Container, LD 6 Container, and LD 11 Container, M 1 Container, Pallets, and Others), By Application (Civil Air Transport, Cargo Air Transport, and Others), By Material Type (Composite, Metal, and Others), By Container Type (Normal Container, Cold Container, and Others) and Regional Forecast, 2020-2027.”, mentions that the market stood at USD 2.15 billion in 2019 and is projected to exhibit a CAGR of 4.38% between 2020 and 2027. Suspended Operations across Aerospace Industry to Affect Growth amid COVID-19 The lockdown announced by government agencies across the globe has led to the suspension of several industrial activities globally. The aerospace industry is going through an economic downturn due to the suspension of manufacturing activities and the ban on international traveling to contain the widespread effect of the global pandemic. This is expected to affect the growth of the market in the near future. However, several companies such as CSafe Global, Cargo Composites, and ACL AIRSHOP have restarted their operational activity to provide efficient ULD solutions to propel the market growth during the forecast period. Get Sample PDF Brochure: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/unit-load-devices-market-103550 List of the Companies Profiled in the Global Unit Load Device Market: ACL AIRSHOP (The U.S.)Brambles Group (Australia)Cargo Composites (The U.S.)CSafe Global (The U.S.)Dokasch GmbH (Germany)Envirotainer AB (Sweden)Nordisk Aviation Products AS (Norway)Palnet GmbH Air Cargo Products (Germany)Satco, Inc. (The U.S.)TransDigm Group Incorporated (The U.S.)VRR Aviation (The Netherland)Zodiac Aerospace (France) A ULD is either an aircraft container or a pallet that is widely adopted across the aviation sector to hold the cargo and baggage during a flight. ULDs allow larger quantities of baggage to be bundled in a single unit and aids in saving the time and effort of the ground crew. Additionally, each ULD consists of its packaging list to track its contents. What does the Report Provide? The market report provides an in-depth analysis of several factors such as the key drivers and restraints that will impact the market. Furthermore, the report includes significant insights into the regional insights that include different regions contributing to the market growth during the forecast period. It includes the competitive landscape involving the leading companies and adopting strategies to introduce new products, announce partnerships, collaborate, and acquire other companies that will contribute to market growth. Moreover, the research analyst has adopted several research methodologies such as PESTEL analysis to obtain information about the current trends and industry developments that will drive the market growth between 2020 and 2027. Inquire Before Buying This Research Report: https://www.fortunebusinessinsights.com/enquiry/queries/unit-load-devices-market-103550 DRIVING FACTORS Growing Adoption of IoT-enabled ULDs to Promote Growth Advanced technologies such as the internet of things (IoT) provide a platform for the implementation of agile infrastructure. This enables the cargo companies to accelerate the cargo loading and unloading operations. In addition to this, the cargo assigned to the unit load device can be tracked accurately due to this technology that significantly saves time and effort of the ground staff while further preventing delayed flights. The rising aviation sector further fuels the demand for lightweight ULDs that have the lowest tare weight and showcase the highest strength-to-weight performance during cargo operations. Therefore, these factors are likely to boost the global unit load devices market growth during the forecast period. SEGMENTATION Cold Container Segment to Hold a Significant Market Share Based on container type, the cold container segment is expected to experience considerable growth due to the growing adoption of cold containers to deliver vital vaccines and medical aid amid the COVID-19 pandemic by the healthcare industry. REGIONAL INSIGHTS North America to Remain Dominant; Increasing Focus on Product Development to Feed Growth Among all the regions, North America is expected to dominate and hold the highest position in the global unit load device market during the forecast period. This dominance is attributable to the increasing focus of established companies to develop advanced unit load device management solutions and the growing procurement of ULDs in the region. North America stood at USD 0.84 billion in 2019. The market in Europe is anticipated to showcase exponential growth in the forthcoming years. This is ascribable to factors such as the growing adoption of advanced temperature management solutions for cold chain applications in the region between 2020 and 2027. COMPETITIVE LANDSCAPE Product Innovation by Eminent Companies to Maintain Their Dominance The global unit load device market is segmented into several companies striving to gain a competitive edge over their rivals and further strengthen their positions. They are focusing on introducing innovative ULDs to cater to the growing demand from aviation, logistics, and healthcare sectors. Moreover, the adoption of organic and inorganic strategies by other key players to maintain their presence is expected to bode well for the growth of the global marketplace. Browse Detailed Summary of Research Report with TOC: https://www.fortunebusinessinsights.com/unit-load-devices-market-103550 Detailed Table of Content: Introduction Research ScopeMarket SegmentationResearch MethodologyDefinitions and Assumptions Executive SummaryMarket Dynamics Market DriversMarket RestraintsMarket Opportunities Key Insights Key Industry Developments – Key Contracts & Agreements, Mergers, Acquisitions and PartnershipsLatest technological AdvancementsPorters Five Forces AnalysisSupply Chain Analysis Quantitative Insights-Impact of COVID-19 Pandemic on Global Unit Load Device Market Impact of COVID-19 Pandemic on Global Unit Load Device MarketSteps Taken by Industry/Companies/Government to Overcome the ImpactKey Development in the industry in Response to COVID-19 PandemicPotential Opportunities due to COVID-19 Outbreak Global Unit Load Device Market Analysis, Insights and Forecast, 2016-2027 Key Findings / SummaryMarket Analysis, Insights and Forecast – By Product Type LD 3 ContainerLD 6 ContainerLD 11 ContainerM 1 ContainerPalletsOthers Market Analysis, Insights and Forecast – By Application Civil Air Transport Cargo Air TransportOthers Market Analysis, Insights and Forecast – By Material Type CompositeMetalOthers Market Analysis, Insights and Forecast – By Container Type Normal ContainerCold ContainerOthers Market Analysis, Insights and Forecast – By Region North AmericaEuropeAsia-pacificRest of the world TOC Continued…! Key Industry Development: March 2020: VRR unveils an updated design of its inflatable AKE container designed to increase the efficiency of the air cargo transportation services globally. The container, according to the company, increases the capacity utilization of the baggage and luggage services. Get your Customized Research Report: https://www.fortunebusinessinsights.com/enquiry/customization/unit-load-devices-market-103550 Have a Look at Related Research Insights: Airport Services Market Size, Share & COVID-19 Impact Analysis, By Type (International, and Domestic), By Application (Aeronautical Services, Non-Aeronautical Services), By Infrastructure Type (Greenfield Airport, Brownfield Airport), and Regional Forecast, 2020-2027 Air Traffic Control Market Size, Share and Industry Analysis, by Point of Sale (Hardware, Software, and Services), By Airspace (Air Route Traffic Control Centers (ARTCC), Terminal Radar Approach Control (TRACON), Air Traffic Control Tower (ATCT), and Remote Tower (RT)), By Application (Communication, Navigation, Surveillance, and Automation), By Airport Size (Small, Medium, and Large),and Regional Forecast, 2020- 2027 About Us: Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in. Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data. At Fortune Business Insights™, we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges. Contact Us: Fortune Business Insights™ Pvt. Ltd. 308, Supreme Headquarters, Survey No. 36, Baner, Pune-Bangalore Highway, Pune - 411045, Maharashtra, India. Phone: US: +1 424 253 0390 UK: +44 2071 939123 APAC: +91 744 740 1245 Email: sales@fortunebusinessinsights.com Read Press Release: https://www.fortunebusinessinsights.com/press-release/global-unit-load-device-market-10416
The independent Data Monitoring Committee (DMC) of the COVA study recommends start of recruitment of Part 2 of the two-part Phase 2-3 Study (“the COVA Study”)Patient recruitment for Part 2 of the COVA Study will start as soon as regulatory/ethics approvals or permissions are obtained in the relevant jurisdictions Interim Analysis on Part 1 is expected in Q1 2021. PARIS and CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- BIOPHYTIS SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, today announces the recommendation by the DMC to start recruitment for Part 2 of Phase 2-3 of the COVA Study. The COVA Study assesses Sarconeos (BIO101) as a potential treatment for acute respiratory failure associated with COVID-19. The DMC’s recommendation is based on its review of the safety data analysis from the first 20 patients enrolled in the study. Based on the DMC’s recommendation, BIOPHYTIS intends to start patient recruitment for Part 2 of the COVA Study in countries where applicable regulatory approvals or permissions, including Institutional Review Board/Ethics Committee approvals, are obtained. Stanislas Veillet, Chief Executive Officer of BIOPHYTIS, said: “We are extremely pleased to receive the DMC’s recommendation to commence recruitment for Part 2 of the COVA Study. With the deteriorating COVID-19 situation around the world, there is a clear need for new treatment options for elderly patients, or patients with co-morbidities, who are expected to continue to be at high risk of developing severe respiratory manifestations requiring hospitalization, even while vaccines are being rolled-out.” The COVA clinical program (clinicaltrials.gov identifier: NCT04472728) is a global, multicentric, double-blind, placebo-controlled, group-sequential, and adaptive design two-part Phase 2-3 study assessing Sarconeos (BIO101) in patients aged 45 and older, hospitalized with severe respiratory manifestations of COVID-19. Part 1 of the COVA Study is a Phase 2 exploratory proof of concept study providing preliminary data on the safety, and tolerability and activity of Sarconeos (BIO101) in 50 hospitalized patients with severe respiratory manifestations related to COVID-19. Part 2 of the COVA Study will be a Phase 3 pivotal randomized study investigating the safety and efficacy of Sarconeos (BIO101) on the respiratory function of 310 COVID-19 patients (including the 50 patients from Part 1 of the study). Results from the full study (Part 1 and Part 2) are expected in Q2 2021, subject to any COVID-19 related delays and the impact of the current pandemic. About BIOPHYTISBIOPHYTIS SA is a clinical-stage biotechnology company specialized in the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19. Sarconeos (BIO101), our leading drug candidate, is a small molecule, administered orally, being developed as a treatment for sarcopenia in a Phase 2 clinical trial in the United States and Europe (SARA-INT). It is also being studied in a clinical two-part Phase 2-3 study (COVA) for the treatment of severe respiratory manifestations of COVID-19 in Europe, Latin America, and the US. A pediatric formulation of Sarconeos (BIO101) is being developed for the treatment of Duchenne Muscular Dystrophy (DMD). The company is based in Paris, France, and Cambridge, Massachusetts. The company's common shares are listed on the Euronext Growth Paris market (Ticker: ALBPS -ISIN: FR0012816825). For more information visit www.biophytis.com DisclaimerThis press release contains forward-looking statements. While the Company considers its projections to be based on reasonable assumptions, these forward-looking statements may be called into question by a number of hazards and uncertainties, so that actual results may differ materially from those anticipated in such forward-looking statements. For a description of the risks and uncertainties likely to affect the results, BIOPHYTIS' financial position, performance or achievements and thus cause a change from the forward-looking statements, please refer to the "Risk Factors" section of the Company's Annual 2019 Report and the Company’s Half Year 2020 Report available on BIOPHYTIS website (www.biophytis.com). This press release, and the information contained in it, does not constitute an offer to sell or subscribe, nor the solicitation of a purchase or subscription order, of BIOPHYTIS shares in any country. The elements contained in this communication may contain forward-looking information involving risks and uncertainties. The Company's actual achievements may differ materially from those anticipated in this information due to different risk and uncertainty factors. This press release was written in French and English; If there is a difference between the texts, the French version will prevail. BIOPHYTIS Contact for Investor RelationsEvelyne Nguyen, CFO E: evelyne.nguyen@biophytis.com Media contactLife Sci Advisor Sophie Beaumont/Chris Maggos/John HodgsonE: sophie@lifesciadvisors.comT: +33 6 27 74 74 49 Investor RelationsLifeSci Advisors, LLC Sandya von der Weid E: svonderweid@lifesciadvisors.comT: +41 78 680 05 38 PDF: http://ml.globenewswire.com/Resource/Download/db4af808-facd-4369-9c56-9bfd083d9ab5
LONDON and BOSTON, Jan. 19, 2021 (GLOBE NEWSWIRE) -- OKYO (LSE: OKYO; OTCQB: EMMLF), the life sciences and biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain, announces that it has today submitted a patent application for the potential use of chemerin and chemerin analogues for prophylaxis against and treatment of symptoms associated with, or resulting from, infection with SARS-CoV-2 virus, including inflammation due to the cytokine storm caused by COVID-19 disease (“COVID-19”), and acute respiratory distress syndrome (“ARDS”). OKYO has been developing the chemerin molecule as a promising anti-inflammatory treatment for dry-eye disease (“DED”) licensed from researchers at On Target Therapeutics LLC. OKYO has previously announced that it anticipates making an investigational new drug submission with the US Food and Drug Administration for the use of chemerin in the treatment of DED. “Together with On Target Therapeutics LLC, we have been exploring chemerin and associated analogues for other potential therapeutic uses and are now also focusing on chemerin as a novel approach to treating COVID-19 and ARDS patients,” said Dr. Gary S. Jacob, CEO of OKYO. “We are working aggressively to expand this COVID-19 work and will be providing progress on this project as important developments occur.” Dr. Napoleone Ferrara, a member of OKYO’s Scientific Advisory Board, will be spearheading this effort at OKYO to advance chemerin and its associated analogues for the treatment of patients with SARS-CoV-2 virus and ARDS. Dr. Ferrara, winner of the prestigious Lasker award and a member of the National Academy of Sciences USA, was the scientist who isolated vascular endothelial growth factor (VEGF), a discovery that led to the two blockbuster drugs Lucentis® and Avastin® (which together accounted for over US$9 billion in sales in 2019) as well as to the class of anti-VEGF drugs, which are widely used to treat cancer and intraocular neovascular diseases. Dr. Ferrara commented: "We are very excited to be working with our collaborating industry and academic partners to develop this promising addition to the COVID-19 therapeutic armamentarium and, of course, to expedite evaluation in patients as soon as possible. Beyond COVID-19, chemerin, which is a well-established modulator of inflammation, has promise for treating ARDS, a pathological condition that may be triggered by a host of insults to the lungs (e.g., pneumonia, sepsis, pancreatitis and inhalation injury).” About Chemerin and its receptor: The chemerin receptor (“CMKLR1”, also known as ChemR23) is a chemokine like G protein-coupled receptor (“GPCR”) expressed on select populations of cells, including inflammatory mediators (including macrophages, monocytes, plasmacytoid/myeloid dendritic cells and natural killer cells), as well as epithelial cells. Activation of CMKLR1 by its endogenous peptide ligand chemerin is known to modulate inflammation, but natural ligands for CMKLR1 have short half-lives due to rapid inactivation. Discovery of a stable, high potency CMKLR1 agonist (stable lipidated chemerin) by On Target Therapeutics LLC provided an important step toward the development of a new class of anti-inflammatory therapeutics. The person who arranged for the release of this announcement on behalf of the Company was Dr. Gary S. Jacob, Chief Executive Officer of OKYO. Notes for Editors: About OKYO OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF) is a life sciences and biotechnology company admitted to listing on the standard segment of the Official List of the UK Financial Conduct Authority and to trading on the main market for listed securities of London Stock Exchange plc. OKYO is focusing on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain. About Dr. Napoleone Ferrara Dr. Ferrara is a member of The National Academy of Sciences and has received numerous prestigious awards, including the Lasker Award and the Breakthrough Prize in Life Sciences. His research on understanding the role of angiogenesis and vascular endothelial growth factor (VEGF) in cancer development, led to the discovery that VEGF is a key mediator of angiogenesis associated with intraocular neovascular syndromes. This pioneering research led to the clinical development of a humanized anti-VEGF Fab (Ranibizumab, Lucentis®), which has also been approved as a therapy for neovascular age-related macular degeneration (AMD), retinal vein occlusion and diabetic macular edema. Ranibizumab and other anti-VEGF agents have had a dramatic impact on the development of therapies for these blinding disorders. When Lucentis® (Ranibizumab) received FDA approval in late June 2006, the new macular degeneration drug was celebrated as a major medical breakthrough. Dr. Ferrara's research also led to the development and approval of humanized anti-VEGF mAbs (Bevacizumab; Avastin®) for cancer treatment, with Avastin® being one of the bestselling cancer drugs over the last two decades. Lucentis® and Avastin® collectively achieved over $9 billion in sales in 2019. Forward-Looking Statements: Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority. For further information, please visit the Company's website at www.okyopharma.com. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014 Enquiries: OKYO Pharma LimitedGary S. Jacob, Chief Executive OfficerGabriele Cerrone, Non-Executive Chairman+44 (0)20 7495 2379 Optiva Securities Limited (Broker)Robert Emmet+44 (0)20 3981 4173 RedChip Companies Inc. (Investor Relations)Dave Gentrydave@redchip.com+1 407-491-4498
VANCOUVER, Jan. 18, 2021 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments in mental disorders and viral infections, is pleased to announce that Health Canada has confirmed that 2-bromo-LSD is not a controlled substance. According to Health Canada, “the information currently available at the Controlled Substances Directorate, 2-bromo-LSD is NOT CONTROLLED under the Schedules to the Controlled Drugs and Substances Act.” In yesterday’s online edition of Forbes magazine, Ahmad Doroudian, CEO of BetterLife, further emphasized the significant barriers that current regulations impose on development of the current generation of psychedelics and LSD based compounds and advantages of non-controlled second generation psychedelics such as TD-0148A. The full Forbes article can be accessed here. “Confirmation of the non-controlled status of 2-bromo-LSD is a significant first step for BetterLife to initiate our IND-enabling pre-clinical studies of our lead second-generation psychedelic product TD-0148A. BetterLife will not face the significant regulatory hurdles during the development process of TD-0148A that other psychedelic products will have to overcome. We believe that there is a great need for novel non-hallucinogenic treatments of mental disorders that can be dispensed at the pharmacy level and safely administered at home. BetterLife’s TD-0148A is one such treatment,” said Ahmad Doroudian, CEO of BetterLife. About BetterLife Pharma Inc. BetterLife Pharma Inc. is an emerging biotechnology company engaged in the development and commercialization of next generation psychedelic products for the treatment of mental disorders. Utilizing drug delivery platform technologies, BetterLife is refining and developing drug candidates from a broad set of complementary interferon-based technologies which have the potential to engage the immune system to fight virus infections, such as the coronavirus disease (COVID-19) and human papillomavirus (HPV). For further information please visit www.abetterlifepharma.com. Contact Information: Ahmad Doroudian, Chief Executive Officer Email: Ahmad.Doroudian@blifepharma.com Phone: 604-221-0595 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS No securities exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.
The proceeds from the bonds will be used to finance its development strategy, mainly acquisitions, in renewables, in particular €1.7 billion for the acquisition of a 20% interest in Adani Green Energy Limited. Total is a broad energy company that produces and markets fuels, natural gas and electricity. TOTAL SE has no liability for their acts or omissions.
Avolon, the international aircraft leasing company, issued its 2021 outlook paper titled ’Looking to Recovery’. The paper reviews the key trends in the aviation industry for airlines, manufacturers, and lessors, identifying themes that are likely to shape the year ahead and setting out six ‘Fearless Forecasts’ for 2021.
Kosmos Energy (NYSE/LSE: KOS) announced today an oil discovery in the U.S. Gulf of Mexico at the Winterfell infrastructure-led exploration ("ILX") well (Kosmos working interest 17.5%).
TechnipFMC plc (NYSE: FTI) (Paris: FTI) (ISIN:GB00BDSFG982) , in anticipation of the previously announced planned separation (the "Spin-off") into two industry-leading, independent, publicly traded companies: TechnipFMC, a fully integrated technology and services provider, and Technip Energies, a leading engineering and technology player, announced today that TechnipFMC intends to offer $850,000,000 aggregate principal amount of senior unsecured notes due 2026 (the "Notes") in a private offering that is exempt from the registration requirements of the Securities Act of 1933, as amended (the "Securities Act"). TechnipFMC intends to use the net proceeds from the offering of the Notes, together with cash on hand, to (i) fully repay and terminate certain of TechnipFMC’s existing indebtedness, (ii) pay fees and expenses related to the Spin-off and (iii) provide working capital and for general corporate purposes for TechnipFMC.
Kasada acquires 1602 keys Sub-Saharan African hotel portfolio from AccorInvest
Italian government bonds seem resilient in the face of a political crisis as investors back the high-yielding debt, a contrast to sell-offs seen during past episodes of government instability. Italy's government lost its majority last week after a junior coalition party pulled out of Prime Minister Giuseppe Conte's government, stripping his majority in the midst of the COVID-19 pandemic. The news barely shook bond markets, with the gap between Italy and Germany's 10-year yields, the risk premium on Italian bonds, rising just 10 basis points.
Vancouver, British Columbia--(Newsfile Corp. - January 19, 2021) - Better Plant Sciences Inc. (CSE: PLNT) (OTCQB: VEGGF) (FSE: YG3) ("Better Plant") or (the "Company") Is pleased to announce its partially owned subsidiary NeonMind (CSE: NEON) ("NeonMind") has common shares now trading on the Frankfurt Stock Exchange (the "FSE") under the symbol "6UF". As a result, NeonMind's common shares are now cross-listed on the Canadian Securities Exchange and the FSE. Shares of Better Plant ...
Vancouver, British Columbia--(Newsfile Corp. - January 19, 2021) - NeonMind Biosciences Inc. (CSE: NEON) (FSE: 6UF) ("NeonMind"), a psychedelic drug development company, is pleased to announce its common shares are now trading on the Frankfurt Stock Exchange (the "FSE") under the symbol "6FU". As a result, NeonMind's common shares are now cross-listed on the Canadian Securities Exchange and the FSE. NeonMind Lists on the Frankfurt Stock Exchange (FSE: 6UF)To view an enhanced version ...
Cushon, the fintech workplace savings disrupter, today announces the launch of the world's first net zero pension.
